Back to results
US 2020/0370126 A1Published application
Compositions and methods for characterizing cancer
AssigneeThe Regents of the University of Michigan
InventorsAntonio M. Lerario, Dipika Mohan, Gary Hammer
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions, systems, and methods for characterizing cancer and determining a treatment course of action. In particular, the present disclosure relates to compositions, systems, and methods for utilizing gene expression and methylation profiles to stratify and treat adrenocortical carcinoma.
Claims17
A method for characterizing adrenocortical carcinoma (ACC), comprising:
- a) contacting a sample from a subject diagnosed with ACC with reagents for determining the level of expression of at least one of BUB1B, PINK1, and G0S2 and the methylation status of G0S2;
- and
- b) characterizing said ACC as molecular subgroup COC1, COC2, or COC3 based on said level of expression of BUB1B, PINK1, and G0S2 and methylation status of G0S2.
A method of treating ACC, comprising:
- a) contacting a sample from a subject diagnosed with ACC with reagents for determining the level of expression of at least one of BUB1B, PINK1, and G0S2 and the methylation status of G0S2;
- b) characterizing said ACC as molecular subgroup COC1, COC2, or COC3 based on said level of expression of BUB1B, PINK1, and G0S2 and methylation status of G0S2;
- and
- c) administering adjuvant cytotoxic chemotherapy in subjects with COC3 tumors.
1 more element
A method of assaying gene expression and methylation, comprising:
- a) contacting a sample from a subject diagnosed with ACC with reagents for determining the level of expression of at least one of BUB1B, PINK1, and G0S2 and the methylation status of G0S2;
- and
- b) identifying said level of expression of BUB1B, PINK1, and G0S2 and methylation status of G0S2.
17-19. (canceled)
Dependencies are inferred from the claim text.